Laboratory Animal Resource Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB), Gwahak-ro 125, Yuseong-gu, Daejeon, 34141, Republic of Korea.
College of Biosciences & Biotechnology, Chungnam National University, Daejeon, 34134, Republic of Korea.
J Neural Transm (Vienna). 2018 Sep;125(9):1319-1331. doi: 10.1007/s00702-018-1902-4. Epub 2018 Jul 11.
Histone acetylation is a key regulatory factor for gene expression in cells. Modulation of histone acetylation by targeting of histone acetyltransferases (HATs) effectively alters many gene expression profiles and synaptic plasticity in the brain. However, the role of HATs on L-DOPA-induced dyskinesia of Parkinson's disease (PD) has not been reported. Our aim was to determine whether HAT inhibitors such as anacardic acid, garcinol, and curcumin from natural plants reduce severity of L-DOPA-induced dyskinesia using a unilaterally 6-hydroxydopamine (6-OHDA)-lesioned PD mouse model. Anacardic acid 2 mg/kg, garcinol 5 mg/kg, or curcumin 100 mg/kg co-treatment with L-DOPA significantly reduced the axial, limb, and orofacial (ALO) score indicating less dyskinesia with administration of HAT inhibitors in 6-OHDA-lesioned mice. Additionally, L-DOPA's efficacy was not altered by the compounds in the early stage of treatment. The expression levels of c-Fos, Fra-2, and Arc were effectively decreased by administration of HAT inhibitors in the ipsilateral striatum. Our findings indicate that HAT inhibitor co-treatment with L-DOPA may have therapeutic potential for management of L-DOPA-induced dyskinesia in patients with PD.
组蛋白乙酰化是细胞中基因表达的关键调节因子。通过靶向组蛋白乙酰转移酶(HATs)来调节组蛋白乙酰化,可有效改变大脑中的许多基因表达谱和突触可塑性。然而,HATs 在帕金森病(PD)的 L-DOPA 诱导性运动障碍中的作用尚未报道。我们的目的是确定天然植物中的 HAT 抑制剂,如没食子酸、藤黄酚和姜黄素,是否能通过单侧 6-羟多巴胺(6-OHDA)损伤的 PD 小鼠模型减轻 L-DOPA 诱导的运动障碍的严重程度。用 HAT 抑制剂共同治疗 2 mg/kg 没食子酸、5 mg/kg 藤黄酚或 100 mg/kg 姜黄素与 L-DOPA 联合治疗可显著降低轴向、肢体和口面部(ALO)评分,表明在 6-OHDA 损伤的小鼠中运动障碍减轻。此外,在治疗的早期阶段,化合物对 L-DOPA 的疗效没有改变。在同侧纹状体中,HAT 抑制剂的给药可有效降低 c-Fos、Fra-2 和 Arc 的表达水平。我们的研究结果表明,HAT 抑制剂与 L-DOPA 联合治疗可能对管理 PD 患者的 L-DOPA 诱导性运动障碍具有治疗潜力。